PSTI
Yaky Yanay - Chairman of the Board, Chief Executive Officer of Pluristem Therapeutics, Inc.

Person placeholder

Yaky Yanay

Chairman of the Board, Chief Executive Officer since 2017

Total compensation: $786,721
Age: 45

Yaky Yanay is Chairman of the Board, Chief Executive Officer of Pluristem Therapeutics Inc. His work experience includes the following roles: President, Chief Operating Officer at the Company (from February 4, 2014), Chief Financial Officer and Secretary at the Company (from November 1, 2006),Chief Financial Officer of Elbit Vision Systems Ltd. and Co-Chairman of Israel Advanced Technology Industries an umbrella organization representing Israel’s hi-tech and life-science industries. He holds a Bachelor of Business Administration degree from Hamichlala Leminhal. He is a Certified Public Accountant.

Pluristem Therapeutics, Inc. logo

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

  • Pluristem Therapeutics, Inc., Building No. 5, Haifa 31905, Israel
  • pluristem.com
  • 972 7 4710 7259
Messenger